PL2448968T3 - Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta - Google Patents

Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta

Info

Publication number
PL2448968T3
PL2448968T3 PL10739701T PL10739701T PL2448968T3 PL 2448968 T3 PL2448968 T3 PL 2448968T3 PL 10739701 T PL10739701 T PL 10739701T PL 10739701 T PL10739701 T PL 10739701T PL 2448968 T3 PL2448968 T3 PL 2448968T3
Authority
PL
Poland
Prior art keywords
terminaltruncated
protofibrils
amyloid
oligomers
antibodies selective
Prior art date
Application number
PL10739701T
Other languages
English (en)
Polish (pl)
Inventor
Pär GELLERFORS
Lars Lannfelt
Linda SÖDERBERG
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of PL2448968T3 publication Critical patent/PL2448968T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL10739701T 2009-06-29 2010-06-29 Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta PL2448968T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29
PCT/IB2010/052947 WO2011001366A1 (en) 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease
EP10739701.0A EP2448968B1 (en) 2009-06-29 2010-06-29 ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS

Publications (1)

Publication Number Publication Date
PL2448968T3 true PL2448968T3 (pl) 2021-09-13

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10739701T PL2448968T3 (pl) 2009-06-29 2010-06-29 Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta

Country Status (16)

Country Link
US (2) US20120100129A1 (enExample)
EP (2) EP2448968B1 (enExample)
JP (3) JP2012532094A (enExample)
AU (1) AU2010267640B2 (enExample)
CA (1) CA2765602C (enExample)
CY (1) CY1124034T1 (enExample)
DK (1) DK2448968T3 (enExample)
ES (1) ES2864049T3 (enExample)
HR (1) HRP20210611T1 (enExample)
HU (1) HUE053949T2 (enExample)
LT (1) LT2448968T (enExample)
PL (1) PL2448968T3 (enExample)
PT (1) PT2448968T (enExample)
SI (1) SI2448968T1 (enExample)
SM (1) SMT202100237T1 (enExample)
WO (1) WO2011001366A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
RU2555526C2 (ru) 2010-02-26 2015-07-10 Байоарктик Ньюросайенс Аб Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий
AU2012228236B2 (en) * 2011-03-16 2016-10-27 Vivoryon Therapeutics N.V. Diagnostic antibody assay
RS61717B1 (sr) 2014-07-10 2021-05-31 Bioarctic Ab Poboljšana antitela koja vezuju a-beta protofibril
JP2018522891A (ja) 2015-07-21 2018-08-16 バイオアークティック アーベー 凝集ペプチドを標的とする外傷性脳損傷の治療方法
WO2018011353A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN112805031A (zh) 2018-07-24 2021-05-14 卫材R&D管理有限公司 阿尔茨海默病的治疗及预防方法
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
US20220251518A1 (en) * 2019-07-08 2022-08-11 Terumo Kabushik Kaisha Hybridoma, method for making the same, monoclonal antibody, and method for making the same
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
DK4172199T3 (da) 2020-06-26 2025-08-18 Bioarctic Ab Alfa-synuklein-protofibril-bindende antistoffer
US20250163135A1 (en) 2021-07-09 2025-05-22 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
EP4395821A1 (en) 2021-08-30 2024-07-10 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
JP2025506389A (ja) 2022-02-02 2025-03-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ｐ－タウ１８１レベルを使用した治療方法
IL321331A (en) 2022-12-22 2025-08-01 Bioarctic Ab Antibody that binds to ABETAPE3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ES2235926T3 (es) * 1999-08-04 2005-07-16 The University Of Southern California Ensamblaje globular de proteina beta amiloide y sus usos.
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
PL1737891T3 (pl) * 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
KR101581733B1 (ko) * 2007-11-16 2015-12-31 더 락커펠러 유니버시티 원섬유 형태의 베타­아밀로이드 단백질에 대해 특이적인 항체
LT2282758T (lt) * 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams

Also Published As

Publication number Publication date
US20120100129A1 (en) 2012-04-26
ES2864049T3 (es) 2021-10-13
EP2448968B1 (en) 2021-01-27
JP2017197531A (ja) 2017-11-02
DK2448968T3 (da) 2021-04-12
CA2765602A1 (en) 2011-01-06
JP6884025B2 (ja) 2021-06-09
AU2010267640A1 (en) 2012-01-19
LT2448968T (lt) 2021-05-10
SMT202100237T1 (it) 2021-05-07
CA2765602C (en) 2021-05-25
EP3892633A1 (en) 2021-10-13
PT2448968T (pt) 2021-04-30
CY1124034T1 (el) 2022-05-27
JP2019218362A (ja) 2019-12-26
WO2011001366A1 (en) 2011-01-06
JP2012532094A (ja) 2012-12-13
HRP20210611T1 (hr) 2021-05-28
AU2010267640B2 (en) 2015-03-05
US20230295283A1 (en) 2023-09-21
EP2448968A1 (en) 2012-05-09
SI2448968T1 (sl) 2021-07-30
HUE053949T2 (hu) 2021-08-30

Similar Documents

Publication Publication Date Title
SMT202100237T1 (it) Anticorpi selettivi per protofibrille/oligomeri beta-amiloidi troncati n-terminali
ZA201202299B (en) Method for decreasing immunigenicity
GB0905140D0 (en) Method
EP2391894A4 (en) SYSTEM IN RELATIVE TIME
GB0902476D0 (en) Method
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
IL215234A0 (en) Method for purifying recombinant fsh
GB0901444D0 (en) Method
PL2114996T3 (pl) Sposób otrzymywania hipoalergenów
IL208514A0 (en) Process for preparing substituted biphenylanilides
GB0905367D0 (en) Method
GB0903316D0 (en) Method
IL217192A0 (en) Biorefinery method
ZA201203155B (en) Method for isolating methylglycinenitrile-n,n-diacetonitrile
PL2284468T3 (pl) Sposób suszenia zrębków
GB0902034D0 (en) Method
GB0904946D0 (en) Method
GB0900560D0 (en) Method
EP2433942A4 (en) PROCESS FOR THE PREPARATION OF D-BIOTIN
GB0903026D0 (en) Novel method
GB0905332D0 (en) Method
GB2476082B (en) Improved base station architecture
IL199690A0 (en) Hanger for fhelf
GB0922292D0 (en) Novel Method